- CEO
- Le gang Wang
- Full Time Employees
- 5,071
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- No. 208, Zhenzhong Road Hangzhou ZH China 310023
- IPO Date
- Jun 30, 2023
- Business
- Adicon Holdings Limited (9860.HK) is an investment holding company and one of China's top three independent clinical laboratory (ICL) service providers, operating a nationwide network of self-managed medical laboratories that deliver comprehensive diagnostic testing services to hospitals, medical examination centers, pharmaceutical companies, and contract research organizations. The company offers an extensive portfolio exceeding 4,000 testing items, including routine tests, esoteric tests, clinical immunologic testing, clinical chemistry testing, clinical molecular biology testing, and pathology testing; testing services for research and development projects; research and clinical trial services; trading of medical testing equipment; and sale of medical products. Adicon primarily serves the healthcare and biopharmaceutical sectors in mainland China through over 30 laboratories across provinces such as Zhejiang, Shandong, Anhui, Shanghai, Beijing, and others, with a network covering the national market and capabilities in high-throughput testing, data analytics, molecular biology platforms, protein technology platforms, and bioinformatics.
Founded in 2004 by Ji Xun Lin and Feng Lin and headquartered at No. 208, Zhenzhong Road, West Lake District, Hangzhou, People's Republic of China, Adicon Holdings employs approximately 5,445 people and maintains principal operations in the domestic market while expanding globally. Subsidiaries include Adicon International Ltd. in Hong Kong, which supports healthcare services. The company, backed by Carlyle Group, listed on the Hong Kong Stock Exchange in 2023.
In recent developments, Adicon entered a definitive agreement in November 2025 to acquire Crown Bioscience Inc. from JSR Life Sciences for $204 million, aiming to bolster its drug research and development services, translational oncology, precision medicine, and global biopharma client base of over 1,100 companies, with the transaction expected to close in mid-2026 and generate 23.1% of future revenue from outside China. Its 2025 interim results reported revenue of approximately 1.27 billion yuan, up 106% year-on-year, driven by diversified business layout, deepened AI + healthcare initiatives, and CRO revenue growth of 18%, amid strategic partnerships with major hospitals transitioning it from a testing provider to a key collaborator. These moves position Adicon to integrate preclinical CRO with clinical ICL services, enhancing its role in the global pharmaceutical R&D ecosystem.